New quinoline derivatives are aldose reductase inhibitors useful to treat and/or prevent e.g. hyperglycemia, dyslipidemia, insulin resistance, glucose intolerance, diabetes, kidney disease, retinopathies or obesity

Quinoline derivatives of formula (I), their enantiomers, diastereoisomers, and their acid or base addition salts, are new. Quinoline derivatives of formula (I), their enantiomers, diastereoisomers, and their acid or base addition salts, are new. R 11-6C alkyl (substituted by COOR 3 or -NR 4R 5), preferably -(CH 2) 3-COOR 3, -(CH 2) 2-C(Me) 2-COOR 3 or -CH 2-NR 4R 5; R 4-COOR 3 a or 1-6C alkyl (substituted by COOR 3 a); R 3, R 3 aH or 1-6Calkyl; R 51-6C alkyl (substituted by phenyl (optionally substituted by 1-3 substituents of 1-6C alkoxy, 1-6C (polyhalo)alkyl or halo)); R 2phenyl (optionally substituted by 1-6C alkyl, 1-6C alkoxy or 1-6C polyhaloalkyl or halo); and n : 0-8. Independent claims are included for: (1) the preparation of (I); and (2) a combination containing (I) and an antioxidant agent. [Image] ACTIVITY : Antidiabetic; Antilipemic; Metabolic; Cardiovascular-Gen.; Cardiant; Vasotropic; Nephrotropic; Ophthalmological; Antipsoriatic; Gynecological; Nootropic; Osteopathic; Gastrointestinal-Gen; Antiarteriosclerotic; Anorectic; Eating-Disorders-Gen.; Cytostatic; Muscular-gen; Anabolic. MECHANISM OF ACTION : Aldose reductase inhibitor. Composés de formule (I) : dans laquelle :- R1 représente un groupement alkyle substitué ou non par un ou plusieurs groupements COOR3 ou NR4R5,- R2 représente un groupement phényle substitué ou non,- n vaut 0, 1, 2, 3, 4, 5, 6, 7 ou 8Médicaments